AT04A vaccine

a peptide vaccine designed to mimic N-terminal epitope of proprotein convertase subtilisin-kexin type 9 (PCSK9); reduces cholesterol, vascular inflammation, and atherosclerosis in mouse model

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Galabova, Gergana: 1 article (08/2017)
2.	Jukema, J Wouter: 1 article (08/2017)
3.	Juno, Claudia: 1 article (08/2017)
4.	Landlinger, Christine: 1 article (08/2017)
5.	Pieterman, Elsbet J: 1 article (08/2017)
6.	Pouwer, Marianne G: 1 article (08/2017)
7.	Princen, Hans M G: 1 article (08/2017)
8.	Staffler, Guenther: 1 article (08/2017)
9.	van der Hoorn, José W A: 1 article (08/2017)

Related Diseases

1.	Inflammation (Inflammations) 08/21/2017 - "As a consequence, treatment with the AT04A vaccine resulted in a decrease in atherosclerotic lesion area (-64%, P = 0.004) and aortic inflammation as well as in more lesion-free aortic segments (+119%, P = 0.026), compared with control. " 08/21/2017 - "AT04A vaccine induces an effective immune response against PCSK9 in APOE*3Leiden.CETP mice, leading to a significant reduction of plasma lipids, systemic and vascular inflammation, and atherosclerotic lesions in the aorta." 08/21/2017 - "The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice."
2.	Atherosclerosis 08/21/2017 - "The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice."

Related Drugs and Biologics

1.	Lipids
2.	Apolipoproteins E (ApoE)
3.	Cholesterol
4.	Proprotein Convertase 9